Fundz
An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →

Biosergen to merge with Flerie following delisting

RECENTLY ACQUIREDSep 15, 2026•about 2 hours ago

Acquiring Company

Biosergen

Acquired Company

Flerie

SwedenSwedenBiotechnologyHealth CareBiotechnologyFinancial ServicesHealth CareFinanceVenture CapitalAngel InvestmentMedical

Description

Biosergen has applied for the delisting of its shares from the Nasdaq First North Growth Market. This move is conditional upon the completion of its merger with Flerie, indicating a strategic shift for both companies. The merger is expected to enhance their operational capabilities and product offerings.

Company Information

Company

Biosergen

Location

Sweden

About

Biosergen is a biotechnology company focused on developing innovative treatments for fungal infections. The company aims to improve patient outcomes through its specialized therapies. Its groundbreaking research is aimed at addressing unmet medical needs in the healthcare sector.

Don't miss Biosergen's next move

Get an email the moment Biosergen makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Biosergen's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Flerie?

Flerie was acquired by Biosergen, based in Sweden. The deal was reported on September 15, 2026. Biosergen is a biotechnology company focused on developing innovative treatments for fungal infections. The company aims to improve patient outcomes through its specialized therapies. Biosergen is privately held and operates in Biotechnology.

When did Biosergen acquire Flerie?

Biosergen's acquisition of Flerie was reported on September 15, 2026. Biosergen has applied for the delisting of its shares from the Nasdaq First North Growth Market. This move is conditional upon the completion of its merger with Flerie, indicating a strategic shift for both companies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Flerie do?

Flerie AB focuses on developing innovative treatments targeting various medical conditions. The company is engaged in advancing healthcare solutions through strategic mergers. It is privately held, operating in Biotechnology, and is based in Sweden.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.